On June 2, 2025, Opus Genetics, Inc. announced positive topline results from LYNX-2, a pivotal Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75%. The trial targeted significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.
The LYNX-2 study met its primary endpoint, with 17.3% of patients treated with Phentolamine Ophthalmic Solution 0.75% achieving a ≥15-letter improvement in Mesopic Low Contrast Distance Visual Acuity (mLCVA) at Day 15, compared to 9.2% in the placebo group (p<0.05). Patient-reported outcomes also demonstrated improvements in night-driving vision.
This data builds on earlier results and provides evidence of efficacy for a condition that currently has no FDA-approved therapies. The positive outcome reinforces the potential of Phentolamine Ophthalmic Solution 0.75% as a first-in-class treatment for keratorefractive patients experiencing glare, halos, and reduced functional vision in low-light conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.